New therapeutic targets for triple-negative breast cancer were discovered

Breast cancer is divided into three main subtypes: hormone receptor positivity, her2 positive, and triple negative

"Researchers have been able to develop good treatments for hormone receptor-positive and HER2-positive breast cancers, and the long-term survival of patients diagnosed with these types of cancer is fairly good," said Eric Nielsen (ACPP), associate professor of

Nelson's lab specializes in nuclear receptors, a class of proteins

"TLX was previously thought to be a driver of brain and prostate cancer

The researchers then experimented with triple-negative breast cancer cell lines to determine whether an increase in TLX expression reduces the cancer's typical characteristics: tumor growth, migration, invasion, and metastasis

To measure the growth of the cells, the researchers layered the cells on a plate, let them grow, and then measured the DNA content

Cancer cells are also notorious for their ability to break through the inter-tissue barrier, a capability known as aggression that causes tumors to grow in adjacent and distant tissues, a process known as metastasis

"The reduction in transfer is especially important because most deaths are due to the progression of the transfer of the disease," Nelson said

The same features were also measured in mouse models and combined with RNA sequencing to measure changes in TLX expression and histological studies

Despite promising results, the mouse model did not fully capture what was happening in humans

Unfortunately, triple-negative breast cancer is a heterogeneous disease with several subcategories

Nelczyk said: "We want to get a deeper understanding of what TLX is doing, not just in